YOLFTbeta
NeoImmuneTech, Inc.

NeoImmuneTech, Inc.

950220 · KQ · Healthcare / Biotechnology

1,600.00KRW-80.00 (-4.76%)

Price History

Full chart

Market Stats

Previous Close1,680.00
Open1,715.00
Day Range1,590.00 – 1,715.00
52-Week Range1,115.00 – 4,450.00
Volume127.56K
Market Cap66.55B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.49
50-Day Avg1,951.92
200-Day Avg2,433.45

About

NeoImmuneTech, Inc., a clinical-stage T cell-based biotechnology company, develops and sells immuno-therapeutics in Korea. It is developing NT-I7, an IL-7 class T- cell amplifier to treat acute radiation syndrome; and Heterodimer hybrid Fc platform, an antibody platform technology, as well as NT2020, a T cell activator; NT3020, a T cell engager; NT4010, an advanced CAR-T; and NT5010, a TME modifier. The company was incorporated in 2014 and is headquartered in Rockville, Maryland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Tae-Woo Kim CPA
  • Headquarters2400 Research Blvd., Rockville, MD, United States, 20850, Korea
  • Websitehttps://www.neoimmunetech.com

Leadership

  • Mr. Tae-Woo Kim CPAActing CEO, CFO & Director · b. 1980
  • Mr. Gungjin Namgung J.D.Executive VP & COO · b. 1971
  • Mr. Donghoon Choi Ph.D.VP & Chief Scientific Officer · b. 1980
  • Mr. Tae Ho RhoSenior Director & Head of Business Development · b. 1990
  • Ms. Hye JeongSenior Medical Director of Drug Safety and Pharmacovigilance · b. 1970

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue--170.38M94.82M
Growth (%)----44.35%
Gross Profit--170.38M94.82M
Gross Margin--100.00%100.00%
Operating Expense--40.21B25.31B
Operating Income-58.18B-55.62B-40.04B-25.22B
Operating Margin---23497.60%-26596.51%
EBITDA-57.17B-49.83B-36.47B-26.89B
EBITDA Margin---21405.16%-28352.99%
Net Income-60.41B-53.40B-40.88B-31.80B
Net Income Margin---23994.58%-33531.39%
Interest Expense261.39M225.28M726.09M2.42B
Interest Expense % of Total Revenue--426.15%2556.54%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets139.87B90.51B65.43B82.05B
Total Liabilities20.18B15.66B23.76B22.84B
Total Equity119.69B74.86B41.66B59.21B
Cash115.63B68.74B34.17B38.84B

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-42.40B-49.76B-39.06B-25.05B
Capital Expenditure2.48B791.39M1.55B7.19B
Free Cash Flow-44.88B-50.55B-40.61B-32.24B
FCF to OCF105.84%101.59%103.97%128.70%

Key Statistics & Ratios

Market Cap66.55B
Enterprise Value27.24B
Trailing P/E0.00
Forward P/E0.00
Price / Sales37.81
Price / Book0.22
Revenue (TTM)1.76B
Gross Profit (TTM)1.51B
EBITDA-18.29B
Profit Margin0.00%
Operating Margin-362.30%
Return on Equity-61.03%
Return on Assets-21.14%
Shares Outstanding33.53M
Shares Float35.24M
Beta0.49
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jun 10, 20261:5